Noninvasive Cancer Genomics and Exploring Potential Clinical Applications of Circulating Tumor DNAMonday, 23 March 2015 at 12:00  Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.comNovel biomarkers are required to accurately assess tumour burden and response in cancer. Circulating tumour DNA (ctDNA), containing tumour-specific DNA alterations, is present in patient plasma as a fraction of the total cell-free DNA. The study of ctDNA levels and mutational profile could potentially inform clinical decision making, be used to monitor tumour dynamics, assess response to treatment and identify mutations associated with acquired drug resistance. Inivata is a clinical cancer genomics company focused on harnessing the emerging potential of circulating DNA analysis to improve cancer testing and treatment. Novel applications of ctDNA are enabled by Inivata’s technology platform which includes its proprietary enhanced TAm-Seq™ technology, to allow the detection and analysis of genomic material from a cancer patient’s cell-free DNA collected through routinely accessible blood samples. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated. Noninvasive Cancer Genomics and Exploring Potential Clinical Applications of Circulating Tumor DNAMonday, 23 March 2015 at 12:00 Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.comNovel biomarkers are required to accurately assess tumour burden and response in cancer. Circulating tumour DNA (ctDNA), containing tumour-specific DNA alterations, is present in patient plasma as a fraction of the total cell-free DNA. The study of ctDNA levels and mutational profile could potentially inform clinical decision making, be used to monitor tumour dynamics, assess response to treatment and identify mutations associated with acquired drug resistance. Inivata is a clinical cancer genomics company focused on harnessing the emerging potential of circulating DNA analysis to improve cancer testing and treatment. Novel applications of ctDNA are enabled by Inivata’s technology platform which includes its proprietary enhanced TAm-Seq™ technology, to allow the detection and analysis of genomic material from a cancer patient’s cell-free DNA collected through routinely accessible blood samples. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated. Noninvasive Cancer Genomics and Exploring Potential Clinical Applications of Circulating Tumor DNAMonday, 23 March 2015 at 12:00 Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.comNovel biomarkers are required to accurately assess tumour burden and response in cancer. Circulating tumour DNA (ctDNA), containing tumour-specific DNA alterations, is present in patient plasma as a fraction of the total cell-free DNA. The study of ctDNA levels and mutational profile could potentially inform clinical decision making, be used to monitor tumour dynamics, assess response to treatment and identify mutations associated with acquired drug resistance. Inivata is a clinical cancer genomics company focused on harnessing the emerging potential of circulating DNA analysis to improve cancer testing and treatment. Novel applications of ctDNA are enabled by Inivata’s technology platform which includes its proprietary enhanced TAm-Seq™ technology, to allow the detection and analysis of genomic material from a cancer patient’s cell-free DNA collected through routinely accessible blood samples. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated. |
Add to Calendar ▼2015-03-23 00:00:002015-03-24 00:00:00Europe/LondonCirculating Biomarkers World Congress 2015Circulating Biomarkers World Congress 2015 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
